Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps she is taking to strengthen guidance for schools in (a) Yeovil Constituency and (b) England on Individual Healthcare Plans for children with Epilepsy.
Answered by Georgia Gould - Minister of State (Education)
Governing bodies must ensure that the arrangements they put in place are sufficient to meet their statutory responsibilities, and that policies, plans, procedures and systems are properly and effectively implemented. This includes the duty under Section 100 of the Children and Families Act 2014 to make arrangements for supporting pupils with medical conditions and the duties under the Equality Act 2010.
The statutory guidance, ‘Supporting pupils at school with medical conditions’, recommends the use of individual healthcare plans as good practice. They can help schools support pupils with medical conditions, providing clarity about what needs to be done, when and by whom. The school, healthcare professionals and parents should agree, based on evidence, when a healthcare plan would be appropriate. The guidance can be found here: https://assets.publishing.service.gov.uk/media/5ce6a72e40f0b620a103bd53/supporting-pupils-at-school-with-medical-conditions.pdf.
The government has committed to reviewing this statutory guidance. Our aim is to ensure that schools are better equipped to support all pupils with medical conditions as part of our wider ambition to create more inclusive schools through the forthcoming Schools White Paper.
Asked by: Anneliese Midgley (Labour - Knowsley)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what proportion of research funding is allocated to epilepsy research; and if she will make an assessment of the adequacy of this proportion.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), has committed a total of over £25.5 million since 2018/19 on epilepsy research, including over £9.5 million in 2024/25. This research spans discovery science and fundamental understanding of the disease, through to new approaches for diagnosis and intervention. MRC also supports epilepsy research within its portfolio of larger investments. For example, this includes a new MRC Centre of Research Excellence (CoRE) in Restorative Neural Dynamics which aims to develop brain stimulation devices to treat a range of conditions including childhood epilepsy, and the UK data platform for Traumatic Brain Injury research (TBI-REPORTER) which includes post-traumatic epilepsy as one of the areas of focus.
The Department of Health and Social Care also funds research through the National Institute for Health and Care Research (NIHR). The NIHR has funded a range of ongoing epilepsy research and has awarded £12.8 million to studies in the last five financial years. The NIHR continues to welcome funding applications for research into any aspect of human health and care, including alternative treatments for epilepsy.
Asked by: Suella Braverman (Reform UK - Fareham and Waterlooville)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to introduce mandatory epilepsy training for (a) employers and (b) employees.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Employers have a key role to play in supporting workers with long-term health conditions or disabilities in the workplace and it is for employers to assess the training requirements for their workforce. However, the Department of Health and Social Care has no plans to introduce mandatory epilepsy training.
The Department for Work and Pensions’ current offer to employers includes a digital information service which provides tailored guidance to businesses to support employees, including epileptic employees, to remain in work.
The service was developed with user-centred design principles. It offers a simple, interactive, and highly usable resource which helps employers to feel more confident having conversations with their employees about health and disability as well as understanding and fulfilling their legal obligations.
This digital service provides tailored guidance on supporting employees in common workplace scenarios involving health and disability. This enables small businesses to self-serve, by guiding them through key processes. Employers are also able to access links to related government products and services as well as links to sources of external expert support including Epilepsy Action and Epilepsy Society.
The digital information service is available at the following link:
Asked by: Anneliese Midgley (Labour - Knowsley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of his Department's funding for epilepsy research.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research into epilepsy via the National Institute for Health and Care Research (NIHR). Between 2020/21 and 2024/25, the NIHR invested £12.8 million in direct research funding on epilepsy. This investment in epilepsy research allows us to continue developing our understanding of the condition and make a real difference to people living with epilepsy, as demonstrated by the examples of impact outlined below.
In 2022, the NIHR-hosted James Lind Alliance (JLA) carried out a UK Epilepsy Priority Setting Partnership (PSP) with epilepsy patients, carers, and service providers to identify the most pressing research priorities for ongoing epilepsy research investment. Many NIHR-funded research projects align to and address the priorities set out by the JLA PSP, boosting epilepsy research. These include:
Other examples of NIHR-funded epilepsy research and impact include:
The NIHR also works closely with other Government funders, including UK Research and Innovation, which is funded by the Department for Science, Innovation and Technology and includes the Medical Research Council, to fund research into epilepsy to improve treatments and prevent poor health outcomes for patients.
The NIHR welcomes funding applications for research into any aspect of human health and care, including epilepsy. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on epilepsy to all NIHR programmes enables maximum flexibility both in terms of amount of research funding a particular area can be awarded, and the type of research which can be funded.
Asked by: Anneliese Midgley (Labour - Knowsley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the cost of epilepsy to (a) the NHS and (b) the wider economy; and how this estimate informs decisions on funding for epilepsy research.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
While the Government has not made a formal estimate of the cost of epilepsy to the National Health Service and the wider economy, we are aware of a report published by Economist Impact in February 2024, titled, The value of action: mitigating the impact of neurological disorders in the United Kingdom, which estimated that idiopathic epilepsy cost the economy £1.7 billion or 0.07% of gross domestic product in 2019. This report is available at the following link:
The Department funds research into epilepsy via the National Institute for Health and Care Research (NIHR). Between 2020/21 and 2024/25, the NIHR invested £12.8 million in direct research funding on epilepsy.
The NIHR welcomes funding applications for research into any aspect of human health and care, including epilepsy. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on epilepsy to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
Asked by: Anna Dixon (Labour - Shipley)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, what steps his Department is taking to reduce delays in Access to Work applications; and if he will take steps to introduce a fast-track process for disability groups with the lowest employment rates, such as epilepsy.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
We are committed to reducing waiting times for Access to Work. We have increased the number of staff processing Access to Work claims by 27% and applications from customers who are about to start a job or who are renewing are prioritised.
The Green Paper launched a consultation on the future of Access to Work which has now concluded. We are considering responses to the consultation and will set out our plans in due course.
Asked by: Baroness Hussein-Ece (Liberal Democrat - Life peer)
Question to the Department for Education:
To ask His Majesty's Government whether the forthcoming Schools White Paper will address the inclusion of children with long-term conditions such as epilepsy.
Answered by Baroness Smith of Malvern - Minister of State (Department for Work and Pensions)
The government understands the impact of epilepsy and other long-term medical conditions on the way pupils feel included and supported in school life. The government has committed to reviewing the statutory guidance ‘Supporting pupils with medical conditions at school’, and we intend to consult on the revised guidance. The current guidance is available attached.
Our aim is to ensure that all schools are confidently able to meet the needs of pupils with medical conditions, including those with epilepsy, as part of our wider ambition to create more inclusive schools through the forthcoming Schools White Paper.
Asked by: Harriet Cross (Conservative - Gordon and Buchan)
Question to the Department for Transport:
To ask the Secretary of State for Transport, for what reason the DVLA continues to rely on postal correspondence for medical driving licence assessments; and whether there are plans to modernise communication methods to allow applicants to communicate with the DVLA electronically, including through email or secure digital platforms.
Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport)
The table below shows the average time the Driver and Vehicle Licensing Agency (DVLA) took to make a licensing decision in cases where a medical condition must be investigated:
Financial Year | Working days |
2025/26 (to end of November) | 51 |
2024/25 | 44 |
2023/24 | 56 |
The table below shows the number of medical driving licence applications that were outstanding on 3 December for the periods requested:
| More than three months | More than six months | More than nine months |
Number of cases | 72,428 | 22,600 | 2,288 |
In 2024/25, the DVLA made more than 830,000 medical licensing decisions. The DVLA aims to process all applications as quickly as possible. However, driving licence applications where a medical condition(s) must be investigated can take longer as the DVLA is often reliant on information from third parties, including medical professionals, before a licence can be issued.
The quickest way to transact with the DVLA is by using its extensive suite of online services. Drivers with diabetes, epilepsy, Parkinson’s disease, visual impairments, sleep conditions or heart conditions can renew their driving licence online.
The DVLA is focusing on delivering significant improvements to digital services for applicants with medical conditions but medical investigations vary widely in their complexity.
The DVLA is currently rolling out a new casework system which is expected to deliver significant improvements to the services provided to drivers with medical conditions. When fully implemented, this will provide improved turnaround times, increased capacity, increased automation, higher levels of digital functionality and increased digital communication. The DVLA is also planning to launch a new medical services platform which will enable more customers to transact online and will increase the use of email communication.
Applicants may be able to continue driving while their application is being processed, providing the driver can meet specific criteria. More information on this can be found at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1180997/inf1886-can-i-drive-while-my-application-is-with-dvla.pdf
Asked by: Harriet Cross (Conservative - Gordon and Buchan)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what the average waiting time has been for the Driver and Vehicle Licensing Agency to process medical driving licence applications in each of the past three years; and what steps are being taken to reduce delays.
Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport)
The table below shows the average time the Driver and Vehicle Licensing Agency (DVLA) took to make a licensing decision in cases where a medical condition must be investigated:
Financial Year | Working days |
2025/26 (to end of November) | 51 |
2024/25 | 44 |
2023/24 | 56 |
The table below shows the number of medical driving licence applications that were outstanding on 3 December for the periods requested:
| More than three months | More than six months | More than nine months |
Number of cases | 72,428 | 22,600 | 2,288 |
In 2024/25, the DVLA made more than 830,000 medical licensing decisions. The DVLA aims to process all applications as quickly as possible. However, driving licence applications where a medical condition(s) must be investigated can take longer as the DVLA is often reliant on information from third parties, including medical professionals, before a licence can be issued.
The quickest way to transact with the DVLA is by using its extensive suite of online services. Drivers with diabetes, epilepsy, Parkinson’s disease, visual impairments, sleep conditions or heart conditions can renew their driving licence online.
The DVLA is focusing on delivering significant improvements to digital services for applicants with medical conditions but medical investigations vary widely in their complexity.
The DVLA is currently rolling out a new casework system which is expected to deliver significant improvements to the services provided to drivers with medical conditions. When fully implemented, this will provide improved turnaround times, increased capacity, increased automation, higher levels of digital functionality and increased digital communication. The DVLA is also planning to launch a new medical services platform which will enable more customers to transact online and will increase the use of email communication.
Applicants may be able to continue driving while their application is being processed, providing the driver can meet specific criteria. More information on this can be found at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1180997/inf1886-can-i-drive-while-my-application-is-with-dvla.pdf
Asked by: Harriet Cross (Conservative - Gordon and Buchan)
Question to the Department for Transport:
To ask the Secretary of State for Transport, how many medical driving licence applications are currently outstanding for more than (a) 3 months, (b) 6 months and (c) 12 months.
Answered by Simon Lightwood - Parliamentary Under-Secretary (Department for Transport)
The table below shows the average time the Driver and Vehicle Licensing Agency (DVLA) took to make a licensing decision in cases where a medical condition must be investigated:
Financial Year | Working days |
2025/26 (to end of November) | 51 |
2024/25 | 44 |
2023/24 | 56 |
The table below shows the number of medical driving licence applications that were outstanding on 3 December for the periods requested:
| More than three months | More than six months | More than nine months |
Number of cases | 72,428 | 22,600 | 2,288 |
In 2024/25, the DVLA made more than 830,000 medical licensing decisions. The DVLA aims to process all applications as quickly as possible. However, driving licence applications where a medical condition(s) must be investigated can take longer as the DVLA is often reliant on information from third parties, including medical professionals, before a licence can be issued.
The quickest way to transact with the DVLA is by using its extensive suite of online services. Drivers with diabetes, epilepsy, Parkinson’s disease, visual impairments, sleep conditions or heart conditions can renew their driving licence online.
The DVLA is focusing on delivering significant improvements to digital services for applicants with medical conditions but medical investigations vary widely in their complexity.
The DVLA is currently rolling out a new casework system which is expected to deliver significant improvements to the services provided to drivers with medical conditions. When fully implemented, this will provide improved turnaround times, increased capacity, increased automation, higher levels of digital functionality and increased digital communication. The DVLA is also planning to launch a new medical services platform which will enable more customers to transact online and will increase the use of email communication.
Applicants may be able to continue driving while their application is being processed, providing the driver can meet specific criteria. More information on this can be found at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1180997/inf1886-can-i-drive-while-my-application-is-with-dvla.pdf